Obesity
Conditions
Interventions
Experimental group (GE), contained 20 patients, who underwent laparoscopic bypass surgery for weight reduction. In this group the Esmolol initial dose of 0.5mg / kg was used followed by continuous inf
Drug
Sponsors
Instituto de Gastroenterologia de Sao Paulo
Universidade Federal de Sao Paulo
Eligibility
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Volunteers between 18 and 50 years; both genders; physical state Wing I or II; submitted to gastroplasty by bypass at the Igesp hospital; who have signed the informed consent form.
Exclusion criteria
Exclusion criteria: Have allergy to research drugs, have respiratory disease; renal; hematological; hepatic; cardiovascular severe; bronchial asthma; psychiatric disorder; cognitive alterations; make prior use antagonists of beta adrenergic receptors; illicit drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the reduction of postoperative pain scores in the esmolol group. The analysis will be done through the numerical scale of pain. It is expected to find a reduction in pain score.;To evaluate the intraoperative consumption of remifentanil in the esmolol group during surgery. It is expected to find a reduction in total remifentanil consumption compared to the placebo group.;To evaluate the consumption of morphine in the postoperative period in the group treated with esmolol during the surgery. It is expected to find a reduction in the total consumption of morphine in the esmolol group. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the incidence of nausea and vomiting in the postoperative period in the first 24 hours. The Examiner will collect this information from the patients surveyed. Along with the pain questionnaire. A reduction in the incidence of postoperative nausea and vomiting is expected. | — |
Countries
Brazil
Contacts
Public ContactVinicius Morais
Instituto de Gastroenterologia de Sao Paulo
Outcome results
None listed